



0848 8 AUG 14 P2:08

SIDLEY AUSTIN LLP
1501 K STREET, N.W.
WASHINGTON, D.C. 20005
(202) 736-8000
(202) 736-8711 FAX

gveron@sidley.com
(202) 736-8387

BEIJING
BRUSSELS
CHICAGO
DALLAS
FRANKFURT
GENEVA
HONG KONG
LONDON

LOS ANGELES
NEW YORK
SAN FRANCISCO
SHANGHAI
SINGAPORE
SYDNEY
TOKYO
WASHINGTON, D.C.

FOUNDED 1866

August 14, 2008

Division of Dockets Management
Food and Drug Administration
5630 Fishers Lane, Room 1061 (HFA-305)
Rockville, Maryland 20852

Re: FDA-2006-P-0137; Date of Approval for Lunesta® (eszopiclone) Tablets

Dear Sir or Madam:

I write on behalf on Sepracor Inc. ("Sepracor"). On December 30, 2005, the above-identified citizen petition was submitted by David Adams of Venable LLP on behalf of Sepracor. Mr. Adams is currently FDA's contact for the citizen petition. Sepracor respectfully requests that FDA change the contact to Sepracor. Accordingly, please direct any future correspondence regarding the above-identified docket to the following:

Andrew I. Koven, Esq.
Matthew P. Blischak, Esq.
Sepracor Inc.
Legal Affairs
84 Waterford Drive
Marlborough, MA 01752
Phone: (508) 481-6700

Please do not hesitate to contact us if you have any questions. Thank you for your assistance with this matter.

Respectfully submitted,

Gary L. Veron
Counsel for Sepracor Inc.

FDA-2006-P-0137

LET-